Interleukin 2, Human (IL-2), BioAssay(TM) ELISpot Kit

Intended Use:\nThis 2.5 hour ELISpot kit is developed to detect and visualize of single cells secreting human IL-2.\n\nPrinciple:\nAdd stimulated cells or cells and stimulant to the wells and incubate at 37 degrees C in CO2 incubator for a specified period. Secreted human IL-2 binds to antibody coated microtiter plate.\nmicrotiter plate coated with human IL-2 Capture Antibody. Cells and unbounded proteins are washed away. Streptavidin-AP or Streptavidin-HRP is added and binds to the biotinylated detection antibody. Unbounded proteins are washed away. Biotinylated detection antibody is added and binds to the secreted human IL-2. Substrate Solution is added. A colored precipitate forms and appears as spots at the sites of human IL-2 secreting location. Each individual spot representing an individual human IL-2 secreting cell.\n\nBackground:\nInterleukin 2 (IL-2) is a lymphokine synthesized and secreted primarily by T helper lymphocytes that have been activated by stimulation with certain mitogens or by interaction of the T cell receptor complex with antigen/MHC complexes on the surfaces of antigen-presenting cells. The response of T helper cells to activation is induction of the expression of IL-2 and receptors for IL-2 and, subsequently, clonal expansion of antigen-specific T cells. At this level IL-2 is an autocrine factor, driving the expansion of the antigen-specific cells. IL-2 also acts as a paracrine factor, influencing the activity of other cells, both within the immune system and outside of it. B cells and natural killer (NK) cells respond to IL-2 when properly activated. The so-called lymphocyte activated killer, or LAK cells, appears to be derived from NK cells under the influence of IL-2.\n\nHuman IL-2 is a glycoprotein with an apparent molecular weight of 15,000-18,000. Natural IL-2 is glycosylated and varying degrees of glycosylation apparently account for the observed range of molecular weights seen on SDS-PAGE. Human IL-2 is synthesized as a polypeptide of 153 amino acid residues. The first 20 amino acids represent a signal sequence that is cleaved to produce the mature factor. The mature protein contains three cysteine residues, two of which form a disulfide bond that is required for biological activity. Murine IL-2 is approximately 63% identical to human IL-2, but contains a unique stretch of repeated glutamine residues. There is marked species cross-reactivity as human IL-2 has been found to be active on murine cell lines. Cells known to produce IL-2 include thymocytes, gamma delta T cells, B cells, CD4+ and CD8+ T cells, and neurons plus astrocytes.\n\nIL-2 is a factor produced and secreted primarily by activated T helper cells that acts as a autocrine factor driving the expansion of antigen-specific cells and as a paracrine factor influencing the activity of a number of other cells including B cells, NK cells and LAK cells. A simplified but useful view of these activities is of lymphocytes expanding under the influence of IL-2 and becoming the target of other cytokines that cause their functional differentiation.\nWith respect to the specific role of IL-2 on the differentiation of T cells, the separation of CD4+ T helper cells into the categories of TH1 and TH2 according to their function in cell mediated or humoral immunity is a concept that is proving useful. In this system each category of cells secretes a characteristic set of cytokines that functions as a network to push the system either towards cellular immunity (delayed type hyper-sensitivity and cellular cytotoxicity) associated with TH1, or towards humoral immunity (antibody-mediated) associated with TH2. IL-2, along with IFN-gamma and TNF-beta, is a defining product of the TH1 subset. Although the TH1 and TH2 subsets are relatively clearly defined in the murine immune system, these categories are not so clear-cut in the human immune system where the designations TH1-like and TH2-like have been suggested.\n\nOther cells under the possible influence of IL-2 are neutrophils, monocytes, and gamma delta T cells, all of which demonstrate either activation, augmented function, or increased survival when exposed to IL-2. Finally, it should be mentioned that IL-2 is finding its way, along with many other cytokines, into the neurosciences as a possible neuromodulator and growth regulator of glial cells. Because of the central role of the IL-2/IL-2R system in mediation of the immune response, it is obvious that monitoring and manipulation of this system has important diagnostic and therapeutic implications. IL-2 has shown promise as an anti-cancer drug by virtue of its ability to stimulate the proliferation and activities of tumor-attacking LAK and TIL (tumor-infiltrating lymphocytes) cells. However, problems with IL-2 toxicity are still of concern and merit investigation.\n\nKit Components:\nA. Microtiter Plates 1x96wells PVDF-bottom Immunospot plates pre-coated with mouse anti-human IL-2 monoclonal antibody. \nB. Positive Control 1x1 vial. Supplied as a lyophilized recombinant human IL-2. Reconstitute with 250 ul Cell Culture Media before use. Use in 1 hour. \nC. Wash Buffer (20x) 1x60ml. Add 1 volume of Wash Buffer (20x) to 19 volume of ddH2O. Use in 1 week. Stored at room temperature. \nD. IL-2 (Biotin)1x11ml Biotinylated mouse anti-human IL-2 monoclonal antibody. Ready to use. \nE. Streptavidin (AP)(100x) 1x120ul. Add 1 volume of Streptavidin (AP)(100x) to 100 volumes of F. (Streptavidin (AP) Diluent) before use. Use in 1 month. Stored at 4 degrees C. \nF. Streptavidin (AP) Diluent 1x11ml. Ready to use.\nG. BCIP/NBT Substrate Solution 1x11ml. Ready to use.\n\nStorage and Stability: \nStore other components at 4C. Stable for at least 6 months. For maximum recovery of product, centrifuge the original vial after thawing and prior to removing the cap.

Prices direct from United States Biological

Quick response times

Exclusive Biosave savings/discounts

SPECIFICATIONS

Catalog Number

I7663-28K

Size

96Tests

Applications

ELISA

Reactivities

Hum

References

1. Academic Press Limited, London, pp.290-300.\n2. Benveniste, E.N. and J.E. Merrill (1986) Nature 321:610.\n3. Biron, C.A., et al. (1990) J. Exp. Med. 171:173.\n4. Carswell, E.A., et al. (1975) Proc. Natl. Acad. Sci., 72: 3666.\n5. Conlon, K., et al.,(1995) Eur. J. Immunol. 25:644.\n6. Dinarello, C. A. (1994) Eur. Cytokine Netw. 5:513.\n7. Djeu, J.Y., et al. (1993) J. Immunol. 150:960.\n8. El Bakkouri K, et al. (2005), J Gene Med. 7:189.\n9. Espinoza-Delgado, I., et al. (1995) J. Leukoc. Biol. 57:13.\n10. Grimm, E.A., et al. (1982) J. Exp. Med. 155:1823.\n11. Hanisch, U-K., et al. (1993) J. Neurosci. 13:3368.\n12. Hohmann, H.P., et al. (1989) J Biol. Chem. 264: 14927.\n13. Hatakeyama, M. and T. Taniguchi (1990) \"Interleukin-2\" in Peptide Growth Factors and Their Receptors I, Sporn, M.B. and Roberts, A. B., eds. Springer-Verlag, New. York, p. 523\n14. Henney, C.S., et al. (1981) Nature 291:335.\n15. Jue, D.M., et al. (1990) Biochem. 29: 8371.\n16. Kashima, K., et al. (1985) Nature 313:402.\n17. Kelley, V.J., et al. (1988) J. Immunol. 140:59.\n18. Kindler, V., et al. (1995) Eur. J. Immunol. 25:1239.\n19. Kirkman, R.A., et al. (1985) J. Exp. Med. 162:358.\n20. Kjeldsen-Kragh, J., et al. (1993) Eur. J. Immunol. 23:2092.\n21. Kriegler, M., et al. (1988) Cell. 53:45.\n22. Lotze, M.T., et al. (1981) Cancer Res. 41:4420.\n23. Morgan, D.A., et al. (1976) Science 193:1007.\n24. Mossman, T.R. and R.L. Coffman (1989) Annu. Rev. Immunol. 7:145.\n25. Mozes, T., et al. (1991) Immunol Lett. 27: 157.\n26. Nistico, G. and G. De Sarro (1991) Trends Neurosci. 14:146.\n27. Olekowicz, L., et al. (1994) Br. J. Haematol. 88:892.\n28. O'Malley BW Jr., et al (2005), Laryngoscope. 115:391\n29. Ortaldo, J.R., et al. (1984) J. Immunol. 133:779.\n30. Pfeffer, K., et al. (1993) Cell. 73: 457.\n31. Pujol-Borrell, R., et al. (1987) Nature 326:304.\n32. Robertson, M.J. and J. Ritz (1992). Chapter 12 in NK Mediated Cytotoxicity.\n33. Rosenberg, S.A., et al. (1986) Science 233:1318.\nS7.5(00) IL-2 SL10025E 6\n34. Rosenberg, S.A., et al. (1987) N. Eng. J. Med. 316:889.\n35. Rosenberg, S.A. (1988) Ann. Surg. 208:121.\n36. Rubin, J.T. (1993) Cancer Invest. 11:460.\n37. Shibuya, A., et al. (1993) Blood 81:1819.\n38. Siegel, J.P., et al. (1987) Science 238:75.\n39. Simpson, M.A. (1991) Arch. Surg. 126:717.\n40. Smith, K.A. (1980) Immunol. Rev. 51:337.\n41. Smith, K.A. (1984) Annu. Rev. Immunol. 2:319.\n42. Smith, K.A. (1988) Science 240:1169.\n43. Smith, K.A. (1993) Blood 81:1414.\n44. Spagnoli, G.C., et al. (1993) Cell. Immunol. 146:391.\n45. Swain, S.L. (1991) Curr. Opin. Immunol. 3:304.\n46. Tadatsugu,T, et al. (11983) Nature 302: 305.\n47. Tartaglia, L.A., et al. (1991) Proc. Natl. Acad. Sci. USA 88:3535.\n48. Tartaglia, L.A., et al. (1993) Cell. 73: 213.\n49. Thomson, A. (1994) In The Cytokine Handbook (eds K.J. Tracey).\n50. Tracey, K.J., et al. (1987) Nature 330:662.\n51. Trinchieri, G., et al. (1984) J. Exp. Med. 160:1147.\n52. Tsudo, M., et al. (1987) Proc. Natl. Acad. Sci. USA 84:5394.\n53. Tsukaguchi, K., et al. (1995) J. Immunol. 154:1786.\n54. Waage, A., et al.(1987) Lancet. 1:355.\n55. Waldmann, T.A., et al. (1984) J. Exp. Med. 160:1450.\n56. Xin, Z., et al. (1994) J. Neuroimmunol. 54:59.\n57. Yang, S.C., et al. (1991) Cancer Res. 51:3669.\n58. Zubler, R.H., et al. (1984) J. Exp. Med. 160:1170.